Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1648-1655

  Inagaki, Atsushi ^a   Tajima, Emi ^a   Uranishi, Miyuki ^a   Totani, Haruhito ^a   Asao, Yu ^a   Ogura, Hiroka ^a   Masaki, Ayako ^a   Yoshida, Tatsuya ^a   Mori, Fumiko ^a   Ito, Asahi ^a   Yano, Hiroki ^b   Ri, Masaki ^a   Kayukawa, Satoshi ^c   Kataoka, Takae ^c   Kusumoto, Shigeru ^a   Ishida, Takashi ^a   Hayami, Yoshihito ^a   Hanamura, Ichiro ^d   Komatsu, Hirokazu ^a   Inagaki, Hiroshi ^a   Matsuda, Yasufumi ^e   Ueda, Ryuzo ^a   Iida, Shinsuke ^a   more..

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Kainan Hospital   (Japan)

^c Nagoya Memorial Hospital   (Japan)

^d AICHI MEDICAL UNIVERSITY   (Japan)

^e SRL INC   (Japan)

Author keywords

C MAF; CCND1; FGFR3; FISH; Multiple myeloma; PCR; Survival

Indexed keywords

BORTEZOMIB; CYCLIN D1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; MESSENGER RNA; THALIDOMIDE; TRANSCRIPTION FACTOR C MAF;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84888134921     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.026     Document Type: Article

References (34)

1. McKenna R.W., Kyle R.A., Kuehl W.M., Grogan T.M., Harris N.L., Coupland R.W. Plasma cell myeloma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 202-207. International Agency for Research on Cancer (IARC), Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Fonseca R., Bergsagel P.L., Drach J., Shaughnessy J., Gutierrez N., Stewart A.K., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
3. Iida S., Ueda R. Multistep tumorigenesis of multiple myeloma: its molecular delineation. Int J Hematol 2003, 77:207-212.
4. Robillard N., Avet-Loiseau H., Garand R., Moreau P., Pineau D., Rapp M.J., et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003, 102:1070-1071.
5. Hoyer J.D., Hanson C.A., Fonseca R., Greipp P.R., Dewald G.W., The Kurtin P.J. (11;14)(q13;q32) translocation in multiple myeloma, A morphologic and immunohistochemical study. Am J Clin Pathol 2000, 113:831-837.
6. Garand R., Avet-Loiseau H., Accard F., Moreau P., Harousseau J.L., Bataille R.T (11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
7. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., et al. Intergroupe Francophone du Myélome, Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583.
8. Fonseca R., Blood E.A., Oken M.M., Kyle R.A., Dewald G.W., Bailey R.J., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
9. Soverini S., Cavo M., Cellini C., Terragna C., Zamagni E., Ruggeri D., et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003, 102:1588-1594.
10. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109:3489-3495.
11. Chang H., Sloan S., Li D., Zhuang L., Yi Q.L., Chen C.I., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004, 125:64-68.
12. Keats J.J., Reiman T., Maxwell C.A., Taylor B.J., Larratt L.M., Mant M.J., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
13. Jaksic W., Trudel S., Chang H., Trieu Y., Qi X., Mikhael J., et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005, 23:7069-7073.
14. Gertz M.A., Lacy M.Q., Dispenzieri A., Greipp P.R., Litzow M.R., Henderson K.J., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
15. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
16. Tajima E., Uranishi M., Iida S., Komatsu H., Nitta M., Ueda R. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma. Haematologica 2005, 90:559-562.
17. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
18. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
19. Annunziata C.M., Hernandez L., Davis R.E., Zingone A., Lamy L., Lam L.T., et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011, 117:2396-2404.
20. Popovic R., Licht J.D. M.E.K and MAF in myeloma therapy. Blood 2011, 117:2300-2302.
21. Raje N., Hideshima T., Mukherjee S., Raab M., Vallet S., Chhetri S., et al. Preclinical activity of P 276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009, 23:961-970.
22. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105:2941-2948.
23. Xin X., Abrams T.J., Hollenbach P.W., Rendahl K.G., Tang Y., Oei Y.A., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006, 12:4908-4915.
24. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. VISTA Trial Investigators, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
25. Reece D., Song K.W., Fu T., Roland B., Chang H., Horsman D.E., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114:522-525.
26. Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin-Charbonnel C., Caillot D., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
27. Chang H., Trieu Y., Qi X., Xu W., Stewart K.A., Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007, 31:779-782.
28. Pineda-Roman M., Zangari M., Haessler J., Anaissie E., Tricot G., van Rhee F., et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008, 140:625-634.
29. Avet-Loiseau H., Soulier J., Fermand J.P., Yakoub-Agha I., Attal M., Hulin C., et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010, 24:623-628.
30. Kalff A., Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J 2012, 2:e89.
31. Avet-Loiseau H., Malard F., Campion L., Magrangeas F., Sebban C., Lioure B., et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood 2011, 117:2009-2011.
32. Morgan G.J., Gregory W.M., Davies F.E., Bell S.E., Szubert A.J., Brown J.M., et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
33. Chesi M., Bergsagel P.L. Many multiple myelomas: making more of the molecular mayhem. Hematol Am Soc Hematol Educ Program 2011, 2011:344-353.
34. Stralen E., Leguit R.J., Begthel H., Michaux L., Buijs A., Lemmens H., et al. MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20)(q32;q12) in multiple myeloma patients. Leukemia 2009, 23:801-803.